Epivir
Product Images NDC 54868-3693

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Epivir (NDC 54868-3693). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Epivir 150mg Tablet Label (150mg Package Label)

EPIVIR 150 mg tablets packaging label from Physicians Total Care, Inc. The label indicates the product contains 30 tablets. It includes usage cautions and storage instructions, a barcode, and the National Drug Code (NDC) 54868-3693-3. The active ingredient is lamivudine.*

FDA Label Image

Epivir 300mg Tablet Label (300mg Package Label)

Packaging label for EPIVIR 300MG distributed by Physicians Total Care, Inc. The label includes product NDC 54868-5416-0, lot number 0000, expiration date 01/60, and manufacturer information for Glaxo Smith Kline, Research Triangle NC 27709. A barcode and numeric code 54160300000 are also present.*

FDA Label Image

Lamivudine Structural Formula (A558b5c0 D64f 4266 9368 27b19f7e8083 01)

Chemical structure diagram of the active ingredient in EPIVIR. The structure shows a pyrimidine base connected to a sugar ring containing sulfur and hydroxyl groups, depicting the molecular composition relevant to this pharmaceutical product.*

FDA Label Image

Figure 1. Systemic Clearance (l/hr•kg) Of Lamivudine In Relation To Age (A558b5c0 D64f 4266 9368 27b19f7e8083 02)

A line graph depicting the relationship between age in years (x-axis) and systemic clearance (y-axis). The graph shows a declining trend in systemic clearance as age increases from 0 to 60 years.*

FDA Label Image

Figure 2. Virologic Response Through Week 48, Epv20001ab (intent-to-treat) (A558b5c0 D64f 4266 9368 27b19f7e8083 03)

A line graph showing the proportion of patients with HIV-1 RNA less than 400 copies/mL over 48 weeks of treatment with EPIVIR. It compares two dosage regimens: 150 mg twice daily and 300 mg once daily, with proportions increasing and then plateauing over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.